Tadiran Group: The Cash Bridge, the Cost of Funding, and What Series 5 Really Bought

The main article argued that Tadiran’s near-term problem was not a covenant break but the quality of funding holding the bridge period together. This follow-up isolates that exact issue: what the 2025 cash picture actually says, why Series 5 was a refinancing move rather than growth fuel, and what price the company paid to buy that delay.

The core point is simple. By the end of 2025 Tadiran did not have an equity problem or a covenant problem. It had a funding-quality problem. At the group level, cash flow from operations fell to NIS 33.1 million, more than NIS 100 million of all-in cash deficit was left before new debt, and at the parent-company level only NIS 721 thousand of cash remained. So Series 5 was not raised to open a new strategic chapter. It was raised to replace two NIS 100 million bank bullets with longer public debt.

That matters because the move really did improve the timetable. It matters just as much because the price was not limited to a stated 2.5% coupon. Once the warrants and the consideration attributed to the bonds are brought into the picture, what emerges is a credit market that was still willing to fund Tadiran, but not without demanding real compensation.

The Cash Picture That Led to the Refinance

To read 2025 correctly, the right lens here is all-in cash flexibility. This is not a question of how much cash the business could have produced in a normalized year. It is the question of how much cash was actually left after reported CAPEX, leases, dividends, principal repayments, and other real cash uses. That is the relevant test because the thesis here is financing flexibility.

On a consolidated basis, year-end 2025 did not look like a cliff edge, but it did not look comfortable either. The group had NIS 41.4 million of cash and cash equivalents, but it also had NIS 60.7 million of restricted deposits on the balance sheet. So it is wrong to read the whole liquidity layer as freely usable cash. At the same time, cash flow from operations fell to only NIS 33.1 million from NIS 115.4 million in 2024.

The key number is not just operating cash flow. It is what remained after it. In 2025 the group spent NIS 31.8 million on property, investment property and intangible assets, NIS 14.3 million on restricted deposits, NIS 21.9 million on the put-option exercise for non-controlling interests, NIS 27.1 million on lease repayments, NIS 19.1 million on dividends, and NIS 36.0 million on bond and bank-loan principal repayments. Even after including NIS 2.5 million from a business disposal, the all-in gap was NIS 114.5 million before new bank borrowing.

This is the heart of the story. Without the NIS 100 million of new long-term bank borrowing drawn in 2025, and without another refinancing step in early 2026, the year would have ended with much sharper financing friction. That is why Series 5 was not a bonus. It was part of the funding mechanism needed to get through the bridge period.

At the parent-company level, the picture is even sharper. Standalone cash was only NIS 721 thousand at year-end 2025. The company explicitly says its liquidity risk stems from bond repayments, and that this risk depends on the ability of consolidated subsidiaries to repay debt to the company and distribute dividends upward. In other words, anyone looking only at NIS 41.4 million of consolidated cash misses the more important layer: the public debt sits at the parent, but the cash that ultimately services it has to come from the operating subsidiaries.

This also explains why Tadiran had already built a similar funding chain before Series 5. The separate-company disclosures show that proceeds from Series 3 were on-lent to Tadiran Consumer Products and Technology in two loans of about NIS 119 million and NIS 101.5 million, while Series 4 proceeds were on-lent through a NIS 155 million loan, with amortization schedules aligned to the public bonds. That matters because it means Series 5 did not invent a new structure. It extended an existing one in which the parent raises capital-market debt and the operating business is expected to feed that cash back over time.

What Series 5 Actually Bought

Before getting to price, the first question is what was actually purchased. S&P Maalot assigned an ilA+ rating to Series 5 for up to NIS 200 million par and stated that the proceeds were meant mainly to refinance existing financial debt. The company itself also wrote in its board report that it believes it can raise the resources it needs from time to time. Both points matter because they reinforce what the main article already suggested: this was not a rescue issuance.

The December 31, 2025 covenant numbers make that even clearer. Relative to Series 5, the company had NIS 428.1 million of equity versus a minimum threshold of NIS 290 million, a net financial debt-to-balance-sheet ratio of 26.1% versus a ceiling of 72.5%, and an equity-to-balance-sheet ratio of 26.8% versus a 20% floor.

So Series 5 did not buy covenant rescue. It bought funding quality and time.

What exactly was replaced? At the end of 2025 there were two NIS 100 million long-term loans inside Tadiran Consumer Products and Technology. One carried a fixed 5.70% annual rate. The other carried a floating rate based on prime minus 0.52%. Both were due as single bullet payments on August 20, 2027. Both also rested on security over notes, proceeds, receivables, inventory, and cash at the subsidiary.

By contrast, Series 5 is unsecured public debt, carries a fixed 2.5% coupon, and starts paying principal only from June 30, 2028 onward, through six annual payments of 14% of principal from 2028 through 2033 and a final 16% payment in 2034. The shelf-offering report kept flexibility to use the proceeds to repay one of the bank bullets, both of them, or Series 3 principal. The immediate report of March 4, 2026 removes the ambiguity: during February and March 2026 the company repaid the remaining balances of both bank loans.

So what Series 5 actually bought was not excess liquidity but three concrete things. First, it replaced a single NIS 200 million wall in August 2027 with an amortization schedule that stretches to June 2034. Second, economically it shifted the group from secured bank funding at the subsidiary to unsecured public debt at the parent. Third, it gave 2026 a window in which the central question can be operational cash recovery rather than a technical near-term balloon repayment.

But it did not buy three other things. It did not buy new growth. It did not remove the parent’s dependence on upstream cash. And it did not change the fact that in 2025 the business did not fund all of its real cash uses on its own.

The Cost of Funding, Not Just the Stated Coupon

This is the point that is easiest to miss on a first read. The simple headline says Series 5 was issued at a 2.5% fixed, non-indexed coupon. That headline is true, but it does not tell the whole story.

Under the shelf-offering report, each unit was defined as NIS 1,000 par value of bonds plus 5 warrants, at a minimum unit price of NIS 1,016. So even at the initial structure level, the company did not raise clean debt at par. It sold a package. The prospectus also disclosed expected gross proceeds of about NIS 203.2 million, and the annual report later recorded gross proceeds of NIS 203.2 million for NIS 200 million par bonds together with 1 million warrants.

The warrants were not cosmetic. The shelf-offering report estimated the economic value of each warrant at about NIS 39.27, with each warrant exercisable into one share through December 31, 2027 at an exercise price of NIS 200. The immediate report of February 4, 2026 then added the key datapoint: the consideration attributed to each NIS 1 of Series 5 par value was NIS 0.8545, implying a 14.55320% discount on the bonds outstanding.

That is the difference between funding access and funding quality. The credit market did remain open to Tadiran. But to refinance NIS 200 million of bank debt and spread it out over time, the company had to attach an equity-linked sweetener and absorb a meaningful discount at the bond level itself. Put simply, the market said yes to the refinancing, but not on clean plain-vanilla debt terms.

In that sense, Series 5 is a two-sided transaction. On the one hand, it replaced shorter, secured, more concentrated bank loans with a longer public profile, and that is a real improvement in maturity quality. On the other hand, it exposed the price at which that improvement was bought. So anyone looking only at the 2.5% coupon misses the point, and anyone looking only at the 14.55% discount misses the point too. The right reading sits in the middle: Tadiran bought time, but it did not buy it cheaply.

Conclusion

Series 5 did not solve Tadiran’s operating problem. It was not supposed to. What it did was buy real time for a company that reached the end of 2025 with comfortable covenants but weak all-in cash generation, restricted deposits that reduced free liquidity, and a parent company that held almost no standalone cash.

So the right reading is neither “the company raised cheap debt” nor “the company was in immediate debt distress.” The right reading is that the company converted two NIS 100 million bank bullets into a longer and better-shaped funding profile, at a price that shows the market demanded real compensation for the risk and for the bridge period.

That is also what makes 2026 the real test. If Tadiran can bring cash flow from operations back to a level that is more consistent with group EBITDA, and if cash continues to move up to the parent without another refinancing round, Series 5 will look in hindsight like a smart way to buy time. If not, the same move will look less like a structural improvement and more like an expensive postponement of a test the business still has to pass.